2-chloromethyl-1-methyl-4-phenyl-1H-imidazole | 1201687-66-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-chloromethyl-1-methyl-4-phenyl-1H-imidazole
• 英文别名: 2-(chloromethyl)-1-methyl-4-phenylimidazole
• CAS: 1201687-66-2
• 化学式: C₁₁H₁₁ClN₂
• 分子量: 206.675
• InChiKey: OLRVMPFKPCTSFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-chloromethyl-1-methyl-4-phenyl-1H-imidazole 在 sodium hydride 、 对甲苯磺酸 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 、 mineral oil 为溶剂， 反应 16.5h， 生成 2-methyl-5-(2-(1-methyl-4-phenyl-1H-imidazol-2-yl)ethyl)pyrazolo[5,1-a]isoquinoline
  参考文献：
  名称：

  Synthesis and SAR study of novel tricyclic pyrazoles as potent phosphodiesterase 10A inhibitors

  摘要：

  Novel pyrazolo[5,1-f][1,6]naphthyridines, pyrazolo[5,1-a][2,6]naphthyridines, pyrazolo[5,1-a][2,7]naphthyridines and pyrazolo[5,1-a]isoquinolines phenylimidazole/benzimidazole ethylene-linked were designed and synthesized for PDE10A interaction. An AgOTf and proline-cocatalyzed multicomponent methodology based on use of o-alkynylaldehydes, tosylhydrazide and ketones was developed and proved to be a convenient route for assembly of most of the novel tricyclic pyrazoles synthesized. Pyrazolo[5,1-f][1,6]naphthyridine 43 and 59, pyrazolo[5,1-a][2,6]naphthyridine 66, and pyrazolo[5,1-a][2,7]naphthyridine 42 showed the highest affinity for PDE10A enzyme (IC50 = 40, 42, 40, 55 nM, respectively).

  DOI：

  10.1016/j.ejmech.2014.07.020
• 作为产物：
  描述：

  methyl 1-methyl-4-phenyl-1H-imidazole-2-carboxylate 在 lithium aluminium tetrahydride 、 氯化亚砜 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 8.0h， 生成 2-chloromethyl-1-methyl-4-phenyl-1H-imidazole
  参考文献：
  名称：

  [EN] TRIAZOLO- AND PYRAZOLOQUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITOR
  [FR] DÉRIVÉS DE TRIAZOLO- ET DE PYRAZOLOQUINAZOLINE EN TANT QU'INHIBITEURS D'ENZYME PDE10A

  摘要：

  本发明涉及式(I)化合物的用途，以及它们作为药物成分的应用，特别是用于治疗与中枢神经系统相关的疾病。

  公开号：

  WO2012007006A1

文献信息

• [EN] PYRROLIDINO HETEROCYCLES<br/>[FR] HÉTÉROCYCLES PYRROLIDINO
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013178569A1

  公开（公告）日：2013-12-05

  The invention relates to compounds of formula I wherein A1, A2, A3, B, R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.

  这项发明涉及公式I的化合物，其中A1、A2、A3、B、R1、R2、R3和R4如描述和索赔中所定义，并且其生理上可接受的盐。这些化合物抑制PDE10A，可用作药物。
• PYRROLIDINO HETEROCYCLES
  申请人：HOFFMANN-LA ROCHE INC.

  公开号：US20150087644A1

  公开（公告）日：2015-03-26

  The invention relates to compounds of formula I wherein A 1 , A 2 , A 3 , B, R 1 , R 2 , R 3 and R 4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.

  这项发明涉及公式I的化合物，其中A1、A2、A3、B、R1、R2、R3和R4如描述和索赔中所定义，并且其生理上可接受的盐。这些化合物抑制PDE10A并可用作药物。
• NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS
  申请人：Ritzén Andreas

  公开号：US20100016303A1

  公开（公告）日：2010-01-21

  This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

  这项发明涉及一类PDE10A酶抑制剂化合物。该发明提供了一种包含所述发明化合物的治疗有效量和药学可接受载体的药物组合物。本发明还提供了制备式I化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法，包括向受试者投予式I化合物的治疗有效量。本发明还提供了一种治疗患有药物成瘾的受试者的方法，包括向受试者投予式I化合物的治疗有效量。本发明还提供了一种治疗患有精神障碍的受试者的方法，包括向受试者投予式I化合物的治疗有效量。
• [EN] NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS<br/>[FR] NOUVEAU DÉRIVÉS DE PHÉNYLIMIDAZOLE CONVENANT COMME INHIBITEURS DE L'ENZYME PDE10A
  申请人：LUNDBECK & CO AS H

  公开号：WO2009152825A1

  公开（公告）日：2009-12-23

  This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective, amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).

  该发明涉及一种PDE10A酶抑制剂的化合物。该发明提供了一种包含该发明化合物的治疗有效量和药用可接受载体的药物组合物。本发明还提供了一种制备公式（I）化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法，包括向受试者投与公式（I）化合物的治疗有效量。本发明还提供了一种治疗患有药物成瘾的受试者的方法，包括向受试者投与公式（I）化合物的治疗有效量。本发明还提供了一种治疗患有精神障碍的受试者的方法，包括向受试者投与公式（I）化合物的治疗有效量。
• Phenylimidazole derivatives as PDE10A enzyme inhibitors
  申请人：H. Lundbeck A/S

  公开号：US08133897B2

  公开（公告）日：2012-03-13

  This invention is directed to phenylimidazole compounds, which are PDE10A enzyme inhibitors useful for the treatment of neurological and psychiatric disorders.

  本发明涉及苯基咪唑化合物，它们是PDE10A酶抑制剂，可用于治疗神经系统和精神疾病。